摘要
目的：观察去甲长春碱（NVB）联合异环磷酰胺（IFO）、顺铂（DDP）组成的INP方案及IFO与DDP和阿霉素（ADM）组成的IAP方案，治疗非小细胞肺癌（NSCLC）的疗效和安全性。方法：52例晚期NSCLC随机分为INP、IAP两组。结果：INP组有效率50．0％IAP组有效率38．4％，两组无显著性差异（P＞0．05）。INP组腺癌有效率64．3％，鳞癌有效率为33．3％IAP组腺癌有效率50．0％，鳞癌有效率28．6％，两组腺、鳞癌之间差异无显著性。两组剂量限制毒性为骨髓抑制，白细胞下降占100％，Ⅲ～Ⅳ度下降INP组为76．9％，IAP组53．8％。消化道反应可以耐受。结论：INP和IAP方案是治疗晚期非小细胞肺癌疗效高、可耐受的理想方案。以诺维本为主的联合方案可推荐作为复治的非小细胞肺癌第二线解救方案。
Objective To evaluate the curative effects and safety of INP NVB＋IFO＋DDP regimen and IAP IFO＋ADM＋DDP regimen for non－small cell lung cancer NSCLC． Methods Fifty－two cases of advanced NSCLC were randomly divided into INP regimen group and IAP regimen group． Results The results showed that the response rates of INP group and IAP group were 50％ and 38．4％ respectively． There was no statistical significant difference between them P＞0．05． The response rates of adenocarcinoma and squamous cell carcinoma were 64．3％ and 33．3％ in INP group P＞0．05 50．0％ and 28．6％ in IAP group P＞0．05． The dose limiting toxicity was neutropenia which was seen in all treated cases 76．9％ and 53．8％ in grade Ⅲ and grade Ⅳ respectively and gastric irritation was tolerable． Conclusion All of these two regimens are effective and tolerable in the treatment of advanced NSCLC． It is recommended that NVB can be used as second－line regimen for retreatment of NSCLC．
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2001年第1期39-41,共3页
Chinese Journal of Clinical Oncology
